A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Active, not recruiting · NCT03033914 · Registry updated 2026-02-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-02-17 | NCT03033914 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Barbara Ann Karmanos Cancer Institute | 29 |
| Bristol-Myers Squibb | 422 |
| British Columbia Cancer Agency | 58 |
| Memorial Sloan Kettering Cancer Center | 753 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BC Cancer (Data Collection Only) | Vancouver | Canada | 1 |
| Hackensack Meridian Health | Hackensack | United States | 22 |
| Karmanos Cancer Institute | Detroit | United States | 153 |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | United States | 189 |
| Memorial Sloan Kettering Bergen | Montvale | United States | 193 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Memorial Sloan Kettering Commack | Commack | United States | 189 |
| Memorial Sloan Kettering Monmouth | Middletown | United States | 206 |
| Memorial Sloan Kettering Nassau | Uniondale | United States | 193 |
| Memorial Sloan Kettering Westchester | Harrison | United States | 204 |